Mar 01, 2021 / 06:30AM GMT
Operator
Hello, and welcome to Oncopeptides Press Conference. (Operator Instructions)
Today, I'm pleased to present CEO, Marty Duvall. Please go ahead with your meeting.
Martin J. Duvall - Oncopeptides AB(publ)-CEO
Thank you, operator, and thanks to everyone who has joined us for this call today. So despite the unusual hour here in Boston, I could not be more excited than to announce the approval of PEPAXTO by the FDA for the treatment of patients with triple-class refractory multiple myeloma.
PEPAXTO. There are times when a brand name and logo just sound, feel and look right. And this is certainly the case for me here, a strong branding link to our company name and the drug, a name that sounds strong and enduring and a mark that linked to our unique PDC platform and drug mechanism of action. I think it's safe to say that we are ready to fly.
So on Slide 2, just to make a disclaimer here that please check our filings for fair balance and accuracy.
And I'll move to Slide 3. So really excited to have
Oncopeptides AB (publ) - Special Call Transcript
Mar 01, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers